Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213156 | 0.83 | ALDH1A1 (0.44) | HCRTR2ALDH1A1HPGDTSHRCOPS5 | |
| SCHEMBL17865363 | 0.83 | HCRTR2 (0.38) | HCRTR2ALDH1A1HPGDTSHRCOPS5 | |
| SCHEMBL15652654 | 0.79 | COPS5 (0.44) | ALDH1A1HPGDCOPS5MAPK1FBP1 | |
| SCHEMBL15650922 | 0.79 | MAPK1 (0.32) | COPS5IKBKBMAPK1 | |
| SCHEMBL17863862 | 0.79 | HCRTR2 (0.41) | HCRTR2ALDH1A1HPGDTSHRMAPK1 | |
| SCHEMBL19668492 | 0.75 | LMNA (0.32) | LMNAPOLB | |
| SCHEMBL8809337 | 0.74 | F2 (0.40) | ALDH1A1HPGDTSHRF2IKBKB | |
| SCHEMBL15121796 | 0.72 | ALDH1A1 (0.44) | ALDH1A1HPGDTSHRF2IKBKB | |
| SCHEMBL1246769 | 0.70 | TBK1 (0.49) | ALDH1A1HPGDIKBKB | |
| SCHEMBL4124036 | 0.69 | ALDH1A1 (0.55) | ALDH1A1HPGDTSHRF2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HCRTR2 2550/4885ALDH1A1 4333/4885HPGD 4082/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HCRTR2 3780/4885ALDH1A1 3674/4885HPGD 3245/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HCRTR2 2550/4885ALDH1A1 4333/4885HPGD 4082/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HCRTR2 2378/4885ALDH1A1 4184/4885HPGD 4156/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HCRTR2 2378/4885ALDH1A1 4184/4885HPGD 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.